Abstract
Pretreatment with R(+)-8-OH-DPAT, a selective serotonin (5-HT)1A receptor agonist (50 micrograms/kg, s.c.), inhibited D-amphetamine sulfate (1.0 mg/kg, s.c.)-induced increases in extracellular levels of both 5-HT and dopamine (DA) in rat medial prefrontal cortex, as determined by in vivo microdialysis. The inhibitory effect of R(+)-8-OH-DPAT was completely reversed by the selective 5-HT1A receptor antagonist WAY 100,635 (100 micrograms/kg s.c.) administered 5 min prior to R(+)-8-OH-DPAT. These results suggest that stimulation of 5-HT1A receptors may inhibit amphetamine-induced release of 5-HT and DA in the medial prefrontal cortex.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology*
-
Amphetamine / antagonists & inhibitors*
-
Animals
-
Anti-Anxiety Agents / pharmacology*
-
Dopamine / metabolism
-
Dopamine Agonists / pharmacology*
-
Drug Evaluation, Preclinical
-
Male
-
Microdialysis
-
Piperazines / pharmacology
-
Prefrontal Cortex / drug effects*
-
Prefrontal Cortex / metabolism
-
Pyridines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Serotonin / metabolism
-
Serotonin Antagonists / pharmacology
-
Serotonin Receptor Agonists / pharmacology*
Substances
-
Anti-Anxiety Agents
-
Dopamine Agonists
-
Piperazines
-
Pyridines
-
Serotonin Antagonists
-
Serotonin Receptor Agonists
-
Serotonin
-
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide
-
8-Hydroxy-2-(di-n-propylamino)tetralin
-
Amphetamine
-
Dopamine